logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Anadys Pharmaceuticals, Inc.

USPTO Granted Patents = 51

% Expired Patents = 62.7



Forward Citations = 316

Loading Chart...
Loading Chart...

68 inventors (with patents filed for the assignee):

goldMedal Stephen Evan Webber (17 out of 54 patents)

silverMedal Peter Scott Dragovich (13 out of 55 patents)

bronzeMedal Douglas Eric Murphy (12 out of 14 patents)

4.  Chinh Viet Tran (11 out of 35 patents)

5.  Frank Ruebsam (11 out of 13 patents)

6.  Joseph R Lennox (9 out of 9 patents)

7.  Erik J Rueden (9 out of 9 patents)

8.  Gregory Jay Haley (9 out of 14 patents)

9.  Alan X Xiang (8 out of 19 patents)

10.  David J Kucera (8 out of 21 patents)

11.  Devron R Averett (7 out of 24 patents)

12.  Yuefen Zhou (7 out of 7 patents)

13.  Liansheng Li (5 out of 117 patents)

14.  C Richard Wobbe (5 out of 11 patents)

15.  Zhongxiang Sun (4 out of 4 patents)


Core Competencies:
Deoxyribofuranose Compounds
TLR7 Ligands
Pyridinone Compounds
Thiazolo Compounds
Antibacterial Agents
Nucleosides
Gene Expression
Hydrazone Derivatives
Hepatitis C Virus
Prodrugs
Antifungal Agents
Screening Methods

51 patents:

1. 9227992 - Method of preparing deoxyribofuranose compounds (2016-01-05),
2. 9161946 - Dosing methods for treating disease (2015-10-20),
3. 9156832 - 5,6-dihydro-1H-pyridin-2-one compounds (2015-10-13),
4. 8883758 - 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof (2014-11-11),
5. 8829168 - Method of preparing deoxyribofuranose compounds (2014-09-09),
6. 8815847 - [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid (2014-08-26),
7. 8765741 - [object Object] (2014-07-01),
8. 8586578 - [object Object] (2013-11-19),
9. 8546602 - 5,6-D hydro-1H-pyridin-2-one compounds (2013-10-01),
10. 8236948 - 5,6-dihydro-1H-pyridin-2-one compounds (2012-08-07),
11. 8222404 - [1,2,4]Thiadiazin-3-yl acetic acid compound and methods of making the acetic acid compound (2012-07-17),
12. 8211863 - Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus (2012-07-03),
13. 8193342 - Method for preparing furanose compounds (2012-06-05),
14. 8129368 - 5,6-dihydro-1H-pyridin-2-one compounds (2012-03-06),
15. 8101800 - [object Object] (2012-01-24),
Company Overview
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California, specializing in the development of innovative therapies in the field of pharmaceutical chemistry. The company focuses on a range of core technologies, including deoxyribofuranose compounds, TLR7 ligands, and various derivatives such as pyridinone and thiazolo compounds. Anadys is dedicated to advancing treatments in areas such as antibacterial agents and gene expression, leveraging its expertise in nucleosides and hydrazone derivatives to address unmet medical needs.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Anadys Pharmaceuticals, Inc. USPTO Patent Assignee Logo
51 Patents

#120 in San Diego, CA

#1,621 in California

#6,893 in US

#13,788 in the World

San Diego, CA (US)
San Diego, CA, United States of America

Anadys Pharmaceuticals, Inc.

Forward Citations = 316

68 inventors:

goldMedal Stephen Evan Webber (17 out of 54 patents)

silverMedal Peter Scott Dragovich (13 out of 55 patents)

bronzeMedal Douglas Eric Murphy (12 out of 14 patents)

4.  Chinh Viet Tran (11 out of 35 patents)

5.  Frank Ruebsam (11 out of 13 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Anadys Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/anadys-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…